THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Raid Aljumaily to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Raid Aljumaily has written about Treatment Outcome.
Raid Aljumaily
Connection Strength
0.083
Treatment Outcome
  1. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
    View in: PubMed
    Score: 0.029
  2. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clin Cancer Res. 2021 01 15; 27(2):447-459.
    View in: PubMed
    Score: 0.029
  3. Harnessing the PD-1 Pathway in Myelodysplastic Syndrome. Am J Ther. 2018 Nov/Dec; 25(6):e711-e712.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES